Noile-Immune Biotech Inc. (4893) AI Stock Analysis

• Market Cap: ¥7.83B
• Dividend Yield: N/A
• Average Volume (3M): 216.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -96.99%
• EPS Growth: 29.33%
• Country: JP
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.96
• Shares Outstanding: 43,276,764
• 10 Day Avg. Volume: 146,320
• 30 Day Avg. Volume: 216,100
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

Noile-Immune Biotech exhibits significant financial challenges, including net losses and negative cash flows, which impact its stock performance. The technical indicators suggest bearish momentum, and the valuation is unappealing due to a negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

Noile-Immune Biotech Inc. Business Overview & Revenue Model

Company Description

Noile-Immune Biotech Inc. (4893) is a biotechnology company focused on the development and commercialization of innovative immunotherapy treatments. The company operates primarily in the pharmaceutical and healthcare sectors, aiming to advance cutting-edge therapies that enhance the immune system's ability to fight cancer and other diseases. Its core products and services revolve around proprietary technologies designed to improve the efficacy and safety of immune-based treatments.

How the Company Makes Money

Noile-Immune Biotech Inc. generates revenue through the development and commercialization of its proprietary immunotherapy products. The company's primary revenue streams include licensing agreements, partnerships with pharmaceutical companies, and milestone payments related to the progress of its drug candidates through clinical trials. Additionally, Noile-Immune Biotech may receive royalties from the commercialization of its licensed technologies and products. Strategic collaborations with other biotech firms and research institutions also play a significant role in advancing its research and development efforts, potentially leading to additional revenue opportunities.

Noile-Immune Biotech Inc. Financial Statement Overview

Summary

Noile-Immune Biotech faces significant challenges with consistent net losses and negative cash flows, despite having a strong balance sheet with no debt and high equity. The company needs to improve its operational efficiency and revenue generation to attain profitability and sustainable cash flow.

Income Statement

The company shows significant volatility in revenue, with total revenue sharply decreasing from 2020 to 2023, followed by a substantial rise in 2024. Gross profit margins are consistently high, but the net profit margin remains negative due to significant net losses. EBIT margins are also negative, indicating operational challenges.

Balance Sheet

Noile-Immune Biotech maintains a strong equity position with no debt, resulting in a debt-to-equity ratio of zero. The equity ratio is high, reflecting financial stability. However, the company has been incurring substantial losses, which may affect future equity levels.

Cash Flow

The company exhibits negative free cash flow, indicating cash outflows exceeding inflows from operations. However, the high cash reserves suggest a buffer against operational cash shortfalls, although reliance on financing inflows could pose future risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.14M	7.59M	316.82M	625.78M	100.73M	97.28M
Gross Profit	7.14M	7.39M	314.56M	618.71M	77.83M	94.31M
EBITDA	-861.55M	-1.07B	-775.39M	-106.34M	-767.51M	-591.67M
Net Income	-864.40M	-964.46M	-1.13B	-386.62M	-795.03M	-636.65M
Balance Sheet
Total Assets	4.58B	4.80B	5.78B	4.64B	4.27B	2.67B
Cash, Cash Equivalents and Short-Term Investments	4.47B	4.67B	5.56B	4.52B	4.14B	2.55B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	96.31M	74.67M	91.49M	340.42M	85.72M	75.88M
Stockholders Equity	4.49B	4.73B	5.69B	4.30B	4.19B	2.60B
Cash Flow
Free Cash Flow	0.00	-887.81M	-873.08M	-107.18M	-777.14M	-300.64M
Operating Cash Flow	0.00	-887.81M	-873.08M	-107.18M	-777.14M	-300.64M
Investing Cash Flow	0.00	557.00K	-5.32M	0.00	-4.03M	0.00
Financing Cash Flow	0.00	2.50M	1.91B	487.62M	2.37B	996.35M

Noile-Immune Biotech Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 181.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4893, the sentiment is Neutral. The current price of 181 is below the 20-day moving average (MA) of 188.85, below the 50-day MA of 181.04, and above the 200-day MA of 171.21, indicating a neutral trend. The MACD of 1.86 indicates Positive momentum. The RSI at 44.72 is Neutral, neither overbought nor oversold. The STOCH value of 17.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4893.

Noile-Immune Biotech Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	83 Outperform	¥2.32T	12.53	12.51%	2.17%	4.04%	21.20%
4578	79 Outperform	¥4.10T	10.19	15.02%	1.67%	10.17%	226.18%
4519	71 Outperform	¥10.34T	26.16	19.92%	1.70%	10.29%	11.37%
4523	67 Neutral	¥1.44T	28.62	5.52%	3.14%	9.43%	56.53%
4564	43 Neutral	¥8.80B	-8.61	-111.82%	―	51.20%	44.10%
4893	41 Neutral	¥7.83B	―	―	―	-96.99%	29.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%